The Zhitong Finance App learned that CITIC Securities published a report stating that through DCF model calculations, Cinda Biotech (01801.HK) was given a reasonable equity value of 105.4 billion yuan in 2024 (corresponding to HK$114.6 billion), corresponding to a target price of HK$70 in 2024, maintaining a “buy” rating.

Zhitongcaijing · 10/17 01:41
The Zhitong Finance App learned that CITIC Securities published a report stating that through DCF model calculations, Cinda Biotech (01801.HK) was given a reasonable equity value of 105.4 billion yuan in 2024 (corresponding to HK$114.6 billion), corresponding to a target price of HK$70 in 2024, maintaining a “buy” rating.